S473
Clinical - Gynaecological
ESTRO 2026
met; sub-millimetric motion (<0.2 mm SD) achieved.
Digital Poster 3502 How Does Uterine Cancer Treatment Impact sexual function? Asma Ghorbel, Hajer Zelaiti, Semia Zarraa, Alia Mousli, Hadhemi Ayedi, Khadija Ben Zid, Najla Attia, Rim Abidi, Ameni Yousfi, Chiraz Nasr Radiotherapy, Salah Azaiez, Tunis, Tunisia Purpose/Objective: Uterine cancers, treated with multimodal approaches including surgery, chemotherapy, radiotherapy, and brachytherapy, often result in significant psychological and physical sequelae that compromise patient femininity and intimacy. This study aimed to assess the prevalence of sexual dysfunction and the extent of deterioration in sexual life following uterine cancer treatment, and to identify its predictive factors. Material/Methods: This was a descriptive cross-sectional study conducted at the Salah Azaïez Institute in Tunis. Sexual function was evaluated using the Female Sexual Function Index (FSFI) scale.Statistical analysis utilized Pearson’s correlation and the Chi-square test. Results: The study included 100 Tunisian women followed for either endometrial (54%) or cervical (46%) cancer.Prior to diagnosis, sexual life was considered important by 38% of women. Sixty-four percent of women were satisfied with their sexual life, and 28% considered it excellent (mean FSFI total score : 32.22; sexual dysfunction prevalence: 5%).After treatment, satisfaction levels dropped to 44% being satisfied, with only 4% reporting an excellent sexual life. The overall prevalence of sexual dysfunction rose sharply to 42% (mean FSFI score: 20.75). The majority of patients (69%) experienced a deterioration in the quality of their sexual life, and 30% reported becoming sexually inactive. Sexual frequency decreased for 86% of women, dropping from an average of 8.51 to 3.3
Conclusion: Adjuvant VC-SBRT using modern VMAT and image-guided delivery achieved excellent 5- year local control (100%), a favourable toxicity profile (no ≥ G3 events), and clinically meaningful QoL gains. SBRT can safely reproduce HDR-VBT-like dose distributions, providing an alternative to brachytherapy in appropriately selected EC patients. Prospective randomized trials are warranted to confirm non-inferiority to HDR-VBT, and to further characterize long-term toxicity and patient-reported QoL outcomes. Keywords: Vaginal Cuff SBRT, Endometrial Cancer
Made with FlippingBook - Share PDF online